Sanofi ties price increases to growth rate; Regeneron to target 7,000 docs on new eczema drug Dupixent; NIH and biotech execs meet White House officials
Five things for pharma marketers to know: Wednesday, December 30, 2015
Twenty percent of publicly funded cancer clinical trials don’t enroll enough patients; KaloBios files for bankruptcy; a new MS campaign in Australia uses bicycles
Five things for pharma marketers to know: Friday, October 16, 2015
The NIH plans to fund fewer but more meaningful studies; the FDA asks for more data about AstraZeneca diabetes drug; payers continue to deny coverage for new hep.-C treatments
The draft would allow drugmakers to share off-label economic data with payers, a practice that until now has been considered taboo, and require the FDA to assess patient experience data in regulatory decisions, in addition to boosting funding for the NIH.
Five things for pharma marketers to know: Thursday, March 5
Lilly delays Phase-III cholesterol drug results; PatientsLikeMe and Walgreens team up for “drug reaction reviews”; Roche skin-cancer drug receives Priority Review.
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix